MediWound (MDWD) Set to Post Earnings on Thursday

Key Points

• MediWound is scheduled to report Q3 2026 results before the market opens November 12, with analysts expecting a loss of about $0.71 per share and revenue of $6.73 million.
• In its previous quarter, the company reported a $0.77-per-share loss, slightly worse than estimates, while revenue of $3.09 million topped consensus of $2.59 million.
• Analyst sentiment is mixed but averages to a “Moderate Buy” rating, with a consensus price target of $33; shares recently opened at $14.20.

MediWound (NASDAQ:MDWD - Get Free Report) is expected to be posting its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect MediWound to announce earnings of ($0.7067) per share and revenue of $6.73 million for the quarter. Investors can check the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:30 AM ET.

MediWound (NASDAQ:MDWD - Get Free Report) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.01). MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%. The company had revenue of $3.09 million during the quarter, compared to the consensus estimate of $2.59 million. On average, analysts expect MediWound to post ($2.37) EPS for the current fiscal year and ($2.30) EPS for the next fiscal year.

MediWound Trading Up 6.0%

Shares of NASDAQ MDWD opened at $14.20 on Thursday. The stock has a 50 day moving average of $13.09 and a 200-day moving average of $15.18. The company has a market capitalization of $182.47 million, a P/E ratio of -7.89 and a beta of 0.07. MediWound has a 12 month low of $11.80 and a 12 month high of $19.70.

Insider Activity at MediWound

In other news, COO Shmuel Hess sold 3,958 shares of the company's stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $12.92, for a total value of $51,137.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 9.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Wall Street Zen upgraded MediWound from a "strong sell" rating to a "sell" rating in a report on Saturday, September 26th. Weiss Ratings cut MediWound from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, September 8th. Oppenheimer reissued an "outperform" rating and set a $30.00 target price (down from $32.00) on shares of MediWound in a research note on Friday, August 14th. Alliance Global Partners reaffirmed a "buy" rating on shares of MediWound in a research report on Wednesday, September 16th. Finally, TD Cowen reaffirmed a "buy" rating on shares of MediWound in a research report on Thursday, September 24th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $33.00.

About MediWound

MediWound Ltd. NASDAQ: MDWD is a commercial-stage biotechnology company focused on developing and marketing innovative enzymatic therapies for complex wounds. The company's products are designed to support the removal of damaged tissue and improve wound management, with an emphasis on severe burns and hard-to-heal chronic wounds.

MediWound's lead product, NexoBrid, is a bromelain-based topical biological product used for the enzymatic removal of eschar, or dead tissue, from deep partial-thickness and full-thickness thermal burns.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.